Gurnet Point Capital and Novo Holdings have completed their acquisition of Paratek Pharmaceuticals in a deal valued at $462 million, according to a news release.
Paratek, founded in 1996 and based in Boston, is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases and other public health